Xantos Biomedicine AG Receives Funding From Sixth EU Framework Program For Angiotargeting Project
Xantos Biomedicine AG announced that it has been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new targets and pathways involved in tumor induced blood vessel formation. The overall aim of the project, which will run for four years, is to create innovative and effective tumor-selective treatment regimes that will replace or complement established tumor therapies.
In addition to the discovery and validation of new targets and inhibitors of blood vessel formation and invasion, the project will involve the implementation of clinical trials. Xantos specific role in the project will be to develop novel cDNA libraries from the vascular transcriptome (the set of all cellular messenger RNA transcripts that are present in the blood vessels) and novel assays for the discovery of angiogenesis modulators. The whole project is supported with EUR 6 million from the EU.
The project integrates the core skills and competencies of an additional thirteen research centers, including two companies, working within the field of angiogenesis. These include: University of Bergen, European Institute of Oncology Milano, University of Uppsala, Netherlands Cancer Institute, University of Maastricht, University of Oxford, VU Medical Center, University of Oulu, Institute of Experimental Medicine, Academy of Sciences Czech Republic, NorLux, the Karolinska Institute and Pharmatarget.
Xantos Biomedicine AG announced that it has been awarded a grant from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology (=BayStMWIVT) for the expansion of its technology platform. The overall aim of the project, which will run for two years, is to create in ... more
Xantos Biomedicine AG and QIAGEN N.V. announced their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen(TM). By combining the capabilities of both companies' platforms cus ... more
Xantos Biomedicine AG announced that it has signed a collaboration agreement with Cryptome Pharmaceuticals Ltd, Melbourne, Australia. Xantos has used XantoScreen(TM) technology to discover novel proteins that mediate proliferation of vascular endothelial cells, which potentially play a role ... more
PharmaTarget aims to accelerate the drug development process by offering its products and services with regard to molecular imaging and the Annexin A5 technology.
We offer Molecular Imaging Services for in vivo analysis of apoptosis. Our clients in the biotech and pharmaceutical industry c ... more
NorLux is a research laboratory in the field of Neuro-Oncology in Europe localized in Bergen Norway and Luxembourg. NorLux represents a state-of-the art research center with a critical mass of competitive scientists within all the three major fields of medical research (basic science, trans ... more